BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
May 30, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative...
BrainStorm Senior Management to Present at BIO 2019
May 28, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
- Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 - - Ralph Kern MD, MHSc, Chief Medical Officer & Chief Operating Officer Round Table Panelist, June 4, 2019 - NEW...
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
May 13, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and LONDON, May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced...
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
May 10, 2019 17:00 ET
|
BrainStorm Cell Therapeutics Inc.
Highlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology platform NEW YORK,...
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
April 30, 2019 04:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
March 28, 2019 04:30 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces Grant of an additional New European Patent for NurOwn®
March 26, 2019 06:30 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
March 14, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm to Host Business Update Conference Call
March 07, 2019 04:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
February 22, 2019 07:30 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...